Rheumatology

GSK plc and Chimagen Biosciences Chengdu Chimagen Biosciences Co Lt), a privately held biotechnology company, announced an agreement for GSK to acquire CMG 1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG 1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.